University Medicine of Goettingen, Department of Psychiatry, Goettingen, Germany.
Neurobiol Aging. 2011 Aug;32(8):1379-87. doi: 10.1016/j.neurobiolaging.2009.08.011. Epub 2009 Sep 24.
In the present work, we investigated the level of IgM autoantibodies directed against different Aβ epitopes as potential diagnostic biomarker for Alzheimer's disease (AD). Anti-Aβ autoantibody levels were measured in 75 plasma samples from patients with AD, individuals with mild cognitive impairment (MCI), and healthy age- and sex-matched controls (HC). To validate the presence of anti-Aβ IgMs, pooled plasma samples were subjected to gel-filtration analysis. The mean level of pGluAβ-IgM (N-terminal truncated starting at position three with pyroglutamate) was significantly decreased in AD patients as compared to HC. In the group of MCI patients there was a significant positive correlation between pGluAβ-IgM and cognitive decline analyzed by MMSE (rho = 0.58, d.f. = 13, p = 0.022). These observations indicate that the level of IgM autoantibodies against pGluAβ is a promising plasma biomarker for AD and correlates with the cognitive status of individuals at risk to develop AD.
在本工作中，我们研究了针对不同 Aβ 表位的 IgM 自身抗体水平作为阿尔茨海默病（AD）的潜在诊断生物标志物。在 75 份来自 AD 患者、轻度认知障碍（MCI）患者和健康年龄及性别匹配对照者（HC）的血浆样本中测量了抗 Aβ 自身抗体水平。为了验证抗 Aβ IgM 的存在，将混合血浆样本进行凝胶过滤分析。与 HC 相比，AD 患者中 pGluAβ-IgM（从位置三开始的 N 端截断，带有焦谷氨酸）的平均水平显著降低。在 MCI 患者组中，pGluAβ-IgM 与 MMSE 分析的认知下降之间存在显著的正相关（rho = 0.58，d.f. = 13，p = 0.022）。这些观察结果表明，针对 pGluAβ 的 IgM 自身抗体水平是 AD 的有前途的血浆生物标志物，并且与处于发展为 AD 风险的个体的认知状态相关。
